Related Experiment Video
Updated: Apr 26, 2026
07:31
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
8.3K
The risk-escalation model: a principled design strategy for early-phase trials
Kennedy Institute of Ethics Journal
|August 12, 2014
Summary
Designing early-phase clinical trials involves balancing volunteer benefit and harm. A "risk-escalation model" using maximin strategies iteratively optimizes therapies for better drug development and clinical care.
Area of Science:
- Clinical Trials
- Biotechnology
- Neuroscience
Background:
- Early-phase clinical trials face ethical dilemmas regarding volunteer safety versus therapeutic potential.
- Optimizing therapies in early phases is crucial for the success of later confirmatory trials and overall drug development.
Purpose of the Study:
- To propose a framework for designing early-phase trials that balances risk and therapeutic optimization.
- To explore strategies for managing risks in early-phase trials using cell therapy for Amyotrophic Lateral Sclerosis (ALS) as a model.
Main Methods:
- The study proposes an iterative application of maximin strategies over successive cohorts and trials.
- This approach is termed the "risk-escalation model" for guiding decision-making in early-phase trials.
Main Results:
- The risk-escalation model provides a structured method for managing uncertainties in early-phase trial design.
- This iterative strategy aims to maximize the probability of informing drug development and clinical care.
Conclusions:
- The risk-escalation model offers a moral principle for ethical decision-making in early-phase clinical trials.
- This approach enhances the optimization of potential therapies, thereby improving the prospects of later-stage trials and patient outcomes.
Related Concept Videos
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
01:28Preclinical Development: Overview
4.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.7K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
96
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
96
01:12Hazard Ratio
751
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
751